According to trial registration site, AB-729 has passed the healthy volunteer part of safety (24 of 24 planned accrued across 4 ascending dose levels)
and is therefore on to the HBV patient part 2 of the study that was contingent on HV safety (3 accrued as of the last update: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377840&isReview=true
Call me boring and talking my book, but this is huge news to this $80M MC company. Taking RNAi efficacy for granted based on all we know about GalNAc and HBV, on-target liver safety is all this is about at this stage of the game.
And who knows, maybe this little $10B deal that happened over the weekend could wake up ABUS Board and mgmt as to the value of 729. Hey, it might even enter Vivek's consciousness.